3-(4-bromophenyl)-5-methyl-4H-1,2-oxazol-5-ol | 1213268-47-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-bromophenyl)-5-methyl-4H-1,2-oxazol-5-ol
• CAS: 1213268-47-3
• 化学式: C₁₀H₁₀BrNO₂
• 分子量: 256.099
• InChiKey: MVPDUHCFLLRIJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  41.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-(4-bromophenyl)but-3-en-2-one 在 N-羟基-4-甲基苯磺酰胺 、 potassium carbonate 作用下， 以 甲醇 、 水 为溶剂， 反应 24.0h， 以69%的产率得到3-(4-bromophenyl)-5-methyl-4H-1,2-oxazol-5-ol
  参考文献：
  名称：

  Efficient and Regioselective Synthesis of 5-Hydroxy-2-isoxazolines: Versatile Synthons for Isoxazoles, β-Lactams, and γ-Amino Alcohols

  摘要：

  An efficient and highly regioselective protocol was developed for the preparation of 5-hydroxy-2-isoxazolines, which have been proved to be versatile synthons for isoxazles, beta-hydroxy oximes, and gamma-amino alcohols. beta-Lactams, commonly embedded in the skeletons of bioactive natural products, were also synthesized in two steps from beta-hydroxy oximes, providing a new strategy for the synthesis of this kind of compounds.

  DOI：

  10.1021/jo1000065

文献信息

• SUBSTITUTED ISOXAZOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, METHODS OF PREPARING SAME, AND USES OF SAME
  申请人：Brittain E.A. Dominic

  公开号：US20080027059A1

  公开（公告）日：2008-01-31

  The invention relates to substituted isoxazolines according to the general formula (I): in which A, R1, R2, R3, R4, Z, X, m, n, and p, are given in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted isoxazolines, to methods of preparing said substituted isoxazolines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases known to be at least in part mediated by HDAC activity or whose symptoms are known to be alleviated by HDAC inhibitors.

  该发明涉及一种按照通式(I)给出的取代异噁唑烷化合物，其中A、R1、R2、R3、R4、Z、X、m、n和p在权利要求中给出，以及其盐，包括所述取代异噁唑烷化合物的制药组合物，制备所述取代异噁唑烷化合物的方法以及将其用于制造治疗至少部分通过HDAC活性介导的疾病或其症状已知可以通过HDAC抑制剂缓解的制药组合物的用途。